Aktienanalyse zu RenovoRx Inc (RNXT)RNXTRenovoRx Inc

RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

RenovoRx Inc is a good buy right now due to its recent strong revenue growth and positive clinical trial results. The stock closed at $1.26, which is significantly below the analyst price target of $14.50, indicating a potential upside of over 1,000%. Additionally, the company reported a record revenue of $909,000 for Q2 2026, reflecting a 61% sequential increase and a 115% year-over-year rise. The main risk is the negative earnings per share (EPS) of -0.06 reported for Q2 2026, which indicates ongoing losses but is improving compared to previous quarters.